Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXS NASDAQ:GERN NASDAQ:LXRX NASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.40-0.4%$2.51$0.96▼$3.87$219.06M2.48759,718 shs350,700 shsGERNGeron$1.15+0.9%$1.43$1.04▼$2.01$731.33M0.611.18 million shs8.11 million shsLXRXLexicon Pharmaceuticals$1.92+1.6%$1.91$0.64▼$2.53$839.53M1.071.84 million shs2.99 million shsRIGLRigel Pharmaceuticals$32.85+2.4%$29.77$18.14▼$52.24$593.55M1.2319,287 shs241,516 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+2.55%-13.93%-5.12%+49.69%+2.12%GERNGeron+3.18%-6.20%-18.93%-28.16%-26.30%LXRXLexicon Pharmaceuticals+0.53%-0.53%-21.58%+11.83%+169.19%RIGLRigel Pharmaceuticals+3.79%+6.05%+9.23%+23.62%+51.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.40-0.4%$2.51$0.96▼$3.87$219.06M2.48759,718 shs350,700 shsGERNGeron$1.15+0.9%$1.43$1.04▼$2.01$731.33M0.611.18 million shs8.11 million shsLXRXLexicon Pharmaceuticals$1.92+1.6%$1.91$0.64▼$2.53$839.53M1.071.84 million shs2.99 million shsRIGLRigel Pharmaceuticals$32.85+2.4%$29.77$18.14▼$52.24$593.55M1.2319,287 shs241,516 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+2.55%-13.93%-5.12%+49.69%+2.12%GERNGeron+3.18%-6.20%-18.93%-28.16%-26.30%LXRXLexicon Pharmaceuticals+0.53%-0.53%-21.58%+11.83%+169.19%RIGLRigel Pharmaceuticals+3.79%+6.05%+9.23%+23.62%+51.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXSCodexis 2.00Hold$5.00108.33% UpsideGERNGeron 2.00Hold$2.50117.39% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.55136.98% UpsideRIGLRigel Pharmaceuticals 2.33Hold$54.5065.91% UpsideCurrent Analyst Ratings BreakdownLatest CDXS, LXRX, GERN, and RIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026RIGLRigel Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.005/26/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026RIGLRigel Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$57.005/13/2026RIGLRigel Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$69.00 ➝ $81.005/11/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.30 ➝ $3.105/8/2026CDXSCodexis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/7/2026RIGLRigel Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/7/2026RIGLRigel Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$71.00 ➝ $69.004/27/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026RIGLRigel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXSCodexis$70.39M3.10N/AN/A$0.56 per share4.29GERNGeron$183.88M4.01N/AN/A$0.35 per share3.29LXRXLexicon Pharmaceuticals$49.80M17.13N/AN/A$0.30 per share6.40RIGLRigel Pharmaceuticals$294.28M2.07$6.90 per share4.76$21.57 per share1.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXSCodexis-$43.97M-$0.37N/AN/AN/A-40.97%-68.09%-23.72%8/12/2026 (Estimated)GERNGeron-$83.50M-$0.11N/A11.50N/A-35.48%-23.31%-10.08%8/5/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)RIGLRigel Pharmaceuticals$367.02M$18.721.759.81N/A121.50%47.99%32.40%8/4/2026 (Estimated)Latest CDXS, LXRX, GERN, and RIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CDXSCodexis-$0.11-$0.10+$0.01-$0.10$14.53 million$15.25 million5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/6/2026Q1 2026GERNGeron-$0.03-$0.01+$0.02-$0.01$50.59 million$51.84 million5/5/2026Q1 2026RIGLRigel Pharmaceuticals$0.7950$0.44-$0.3550$0.44$62.40 million$58.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDXSCodexisN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXSCodexis0.945.365.23GERNGeron0.526.784.96LXRXLexicon Pharmaceuticals0.2418.8018.77RIGLRigel Pharmaceuticals0.042.622.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXSCodexis78.54%GERNGeron73.71%LXRXLexicon Pharmaceuticals74.70%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipCDXSCodexis3.50%GERNGeron1.71%LXRXLexicon Pharmaceuticals14.00%RIGLRigel Pharmaceuticals10.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXSCodexis25090.90 million87.72 millionOptionableGERNGeron70641.52 million630.55 millionOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableRIGLRigel Pharmaceuticals16018.50 million16.57 millionOptionableCDXS, LXRX, GERN, and RIGL HeadlinesRecent News About These CompaniesRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Hold" by AnalystsJune 12 at 2:25 AM | americanbankingnews.comInsider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel PharmaceuticalsJune 5, 2026 | benzinga.comThese 10 small-cap U.S. healthcare companies rank among the market's most attractively valued stocksJune 1, 2026 | seekingalpha.comInsider Selling: Rigel Pharmaceuticals (NASDAQ:RIGL) Director Sells 2,500 Shares of StockMay 29, 2026 | insidertrades.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 27, 2026 | prnewswire.comLilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches CompletionMay 22, 2026 | tipranks.comRigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 CongressMay 21, 2026 | prnewswire.comRigel Pharmaceuticals, Inc. (RIGL) M&A Call - SlideshowMay 20, 2026 | seekingalpha.comRigel Shareholders Approve Equity Plans and Board SlateMay 20, 2026 | tipranks.comRigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?May 14, 2026 | finance.yahoo.comRigel to Present at the 2026 RBC Capital Markets Global Healthcare ConferenceMay 14, 2026 | prnewswire.comThese Analysts Increase Their Forecasts On Arvinas After Q1 ResultsMay 13, 2026 | benzinga.comPfizer, Arvinas ink licensing deal with Rigel for breast cancer therapyMay 13, 2026 | seekingalpha.comRigel snaps up breast cancer drug Veppanu in up to $405m dealMay 13, 2026 | thepharmaletter.comTWhy Rigel Pharmaceuticals, Inc.’s (RIGL) Stock Is Up 10.76%May 13, 2026 | aaii.comARigel Pharmaceuticals, Inc. (RIGL) M&A Call TranscriptMay 12, 2026 | seekingalpha.comRigel Secures Global Rights to VEPPANU Breast Cancer TherapyMay 12, 2026 | tipranks.comRigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast CancerMay 12, 2026 | prnewswire.comRigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comRigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue EstimatesMay 5, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDXS, LXRX, GERN, and RIGL Company DescriptionsCodexis NASDAQ:CDXS$2.40 -0.01 (-0.41%) As of 04:00 PM EasternCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Geron NASDAQ:GERN$1.15 +0.01 (+0.88%) Closing price 04:00 PM EasternExtended Trading$1.16 +0.01 (+0.43%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Lexicon Pharmaceuticals NASDAQ:LXRX$1.92 +0.03 (+1.59%) Closing price 04:00 PM EasternExtended Trading$1.94 +0.02 (+0.78%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Rigel Pharmaceuticals NASDAQ:RIGL$32.85 +0.77 (+2.40%) Closing price 04:00 PM EasternExtended Trading$32.52 -0.33 (-0.99%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
